Hangzhou Solipharma Co., Ltd.
Records under this name other than the patents Hangzhou Solipharma Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.
Back to Hangzhou Solipharma Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,427,528 | Fenofibrate Crystalline Form and Manufacturing Method Thereof Lapsed on the fee record Ended Aug 30, 2026 · High confidence | Lapsed on the fee record | Ended Aug 30, 2026 | High confidence |
| US 11,286,259 | Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof Lapsed on the fee record Ended Mar 29, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 29, 2026 | From the USPTO record |
| US 9,884,856 | Crystal form of Dabrafenib mesylate and preparation method thereof Lapsed on the fee record Ended Feb 6, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 6, 2026 | From the USPTO record |
| US 11,236,077 | Fruquintinib eutectic crystal, preparation method therefor, composition, and uses thereof Lapsed on the fee record Ended Feb 1, 2026 · From the USPTO record | Lapsed on the fee record | Ended Feb 1, 2026 | From the USPTO record |
| US 11,208,382 | Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof Lapsed on the fee record Ended Dec 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended Dec 28, 2025 | From the USPTO record |
| US 11,117,875 | Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod Lapsed on the fee record Ended Sep 14, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 14, 2025 | From the USPTO record |
| US 11,111,248 | Crystal form of 2-(6-methyl-pyridin-2-yl)-3-yl-[6-amido-quinolin-4-yl]-5,6-dihydro-4H-pyrrolo[1,2-B]pyrazole, preparation method therefor and pharmaceutical composition thereof Lapsed on the fee record Ended Sep 7, 2025 · From the USPTO record | Lapsed on the fee record | Ended Sep 7, 2025 | From the USPTO record |
| US 10,995,083 | Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition Lapsed on the fee record Ended May 4, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 4, 2025 | From the USPTO record |
| US 10,954,210 | Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof Lapsed on the fee record Ended Mar 23, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 23, 2025 | From the USPTO record |
| US 10,899,767 | Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof Lapsed on the fee record Ended Jan 26, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 26, 2025 | From the USPTO record |